- Home
- AREN vs RLYB Comparison
AREN vs RLYB Comparison
Compare AREN & RLYB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AREN | RLYB |
|---|---|---|
| Founded | 2016 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 74.3M | 75.9M |
| IPO Year | 2017 | 2021 |
Fundamental Metrics
Financial Performance| Metric | AREN | RLYB |
|---|---|---|
| Price | $1.54 | $15.75 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $8.00 | N/A |
| AVG Volume (30 Days) | 78.7K | ★ 296.5K |
| Earning Date | 05-08-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 191.93 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $16,892,000.00 | $858,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $5.00 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 27.46 | ★ 43.00 |
| 52 Week Low | $1.36 | $0.27 |
| 52 Week High | $7.85 | $15.75 |
Technical Indicators
Market Signals| Indicator | AREN | RLYB |
|---|---|---|
| Relative Strength Index (RSI) | 33.01 | 84.33 |
| Support Level | N/A | $0.55 |
| Resistance Level | $4.47 | N/A |
| Average True Range (ATR) | 0.23 | 0.75 |
| MACD | -0.09 | 0.07 |
| Stochastic Oscillator | 10.53 | 86.61 |
Price Performance
Historical ComparisonAbout AREN The Arena Group Holdings Inc.
The Arena Group Holdings Inc is a tech-powered media company that fuses technology, iconic brands, and marketing to deliver vibrant content and experiences that reach million users each month. The company creates robust digital destinations that delight consumers with powerful journalism, news about things such as favorite sports teams, advice on investing, the inside scoop on personal finance, and the latest on lifestyle essentials. The company has four reportable segments: Sports & Leisure, Finance, Lifestyle, and Platform & Other. The company generates revenue from Sports & Leisure. Geographically, the company operates in United States; and Others. It generates maximum revenue from United States.
About RLYB Rallybio Corporation
Rallybio Corp is a clinical-stage biotechnology company comprised of experienced biopharma industry leaders with extensive research, development, and rare disease expertise with a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases. The company's program, RLYB116, is a differentiated complement component 5 (C5) inhibitor with the potential to treat diseases of complement dysregulation. The Company manages its operations as a single segment for the purposes of allocating resources, assessing performance, and making operating decisions. Rallybio's pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody for the treatment of diseases of iron overload.